BASF Asks FDA To Weigh Whole Sunscreen TEAs, Not Separate Parts
This article was originally published in The Tan Sheet
Executive Summary
The firm’s representatives maintain a “weight-of-evidence” approach comprising repeated dose toxicity, photo-genotoxicity, dermal carcinogenicity and photo-carcinogenicity studies is adequate to establish safety. In public meetings required by the Sunscreen Innovation Act, FDA officials say BASF needs to provide more study data.
You may also be interested in...
BASF Ingredient Suffers Identity Crisis In FDA Review
FDA says BASF must clarify whether tests studied bisoctrizole or the firm’s compound marketed as Tinosorb M, which combines bisoctrizole and other ingredients.
FDA Faults BASF Sunscreen Ingredient Data In Latest TEA Rejection
FDA advises BASF that the information the firm submitted is not sufficient to establish octyl triazone as GRASE. The agency’s third rejection this year of a sunscreen TEA could concern advocates on Capitol Hill and in the industry for using the process for adding ingredients to the OTC sunscreen monograph.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.